{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:24:02Z","timestamp":1767651842787,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.ahj.2011.08.020","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T08:55:04Z","timestamp":1321520104000},"page":"884-892.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function"],"prefix":"10.1016","volume":"162","clinical-trial-number":[{"clinical-trial-number":"nct00089895","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Chiara","family":"Melloni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan K.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Tricoci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans","family":"Van de Werf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Califf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Kristin","family":"Newby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2011.08.020_bb0005","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1067\/mhj.2002.120774","article-title":"Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non\u2013ST-segment elevation acute coronary syndromes","volume":"143","author":"Becker","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2011.08.020_bb0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1067\/mhj.2002.123112","article-title":"Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience","volume":"144","author":"Gilchrist","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2011.08.020_bb0015","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0149-2918(04)90034-3","article-title":"Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function","volume":"26","author":"Gretler","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.ahj.2011.08.020_bb0020","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0735-1097(02)02336-7","volume":"40","author":"Braunwald","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.08.020_bb0025","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"The PURSUIT Trial Investigators","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.08.020_bb0030","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0002-9149(01)02041-0","article-title":"Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)","volume":"88","author":"Tcheng","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.08.020_bb0035","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/hc2901.093504","article-title":"Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention","volume":"104","author":"Gilchrist","year":"2001","journal-title":"Circulation"},{"year":"2005","series-title":"Integrilin\u00ae (eptifibatide) [package insert]","key":"10.1016\/j.ahj.2011.08.020_bb0040"},{"key":"10.1016\/j.ahj.2011.08.020_bb0045","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.08.020_bb0050","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ahj.2005.03.029","article-title":"The EARLY ACS trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non\u2013ST-segment elevation acute coronary syndrome\u2014study design and rationale","volume":"149","author":"Giugliano","year":"2005","journal-title":"Am Heart J"},{"author":"European Medicines Agency","key":"10.1016\/j.ahj.2011.08.020_bb0055"},{"key":"10.1016\/j.ahj.2011.08.020_bb0060","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1517\/14656566.9.11.1869","article-title":"Major bleeding: management and risk reduction in acute coronary syndromes","volume":"9","author":"Cavender","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ahj.2011.08.020_bb0065","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"year":"2001","series-title":"Regression modeling strategies with applications to linear models, logistic regression, and survival analysis","author":"Harrell","key":"10.1016\/j.ahj.2011.08.020_bb0070"},{"key":"10.1016\/j.ahj.2011.08.020_bb0075","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1161\/01.CIR.0000027560.41358.B3","article-title":"Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes","volume":"106","author":"Al Suwaidi","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.08.020_bb0080","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.ehj.2004.08.016","article-title":"Association of glomerular filtration rate on presentation with subsequent mortality in non\u2013ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials","volume":"25","author":"Gibson","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.08.020_bb0085","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/heart.89.9.1003","article-title":"Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from GRACE","volume":"89","author":"Santopinto","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2011.08.020_bb0090","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0735-1097(02)02956-X","article-title":"Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb\/IIIa inhibitors","volume":"41","author":"Freeman","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.08.020_bb0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijcard.2009.03.119","article-title":"Relationship between renal function and outcomes in high-risk patients with non\u2013ST-segment elevation acute coronary syndromes: results from SYNERGY","volume":"144","author":"Spinler","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2011.08.020_bb0100","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.amjcard.2004.08.035","article-title":"Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study)","volume":"94","author":"Dumaine","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2011.08.020_bb0105","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jama.296.11.1377","article-title":"Under-representation of renal disease in randomized controlled trials of cardiovascular disease","volume":"296","author":"Coca","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2011.08.020_bb0110","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial","volume":"356","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2011.08.020_bb0115","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1001\/jama.294.24.3108","article-title":"Excess dosing of antiplatelet and antithrombin agents in the treatment of non\u2013ST-segment elevation acute coronary syndromes","volume":"294","author":"Alexander","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2011.08.020_bb0120","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1016\/j.jacc.2005.09.080","article-title":"Correlates of bleeding events among moderate-to-high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial","volume":"47","author":"Kirtane","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2011.08.020_bb0125","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCULATIONAHA.106.620815","article-title":"Sex differences in major bleeding with glycoprotein IIb\/IIIa inhibitors: results from the CRUSADE initiative","volume":"114","author":"Alexander","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.08.020_bb0130","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.ahj.2010.08.008","article-title":"Changes in glycoprotein IIb\/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA guidelines (CRUSADE) initiative","volume":"160","author":"Mudrick","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2011.08.020_bb0135","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1001\/archinte.160.18.2741","article-title":"Effects of computerized physician order entry on prescribing practices","volume":"160","author":"Teich","year":"2000","journal-title":"Arch Intern Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870311006399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870311006399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:46:08Z","timestamp":1757569568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870311006399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0002870311006399"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2011.08.020","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2011.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}